A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
This study is testing a new cancer vaccine called BNT116 combined with an immunotherapy drug called cemiplimab. Researchers want to see if this combination works better at fighting advanced lung cancer than the immunotherapy drug alone.
This study is for people with advanced, non-removable lung cancer who have high levels of a protein called PD-L1. Participants must be smokers or former smokers and cannot have specific genetic tumor markers like EGFR, ALK, or ROS1.
You will receive the study treatment and have regular check-ups to monitor your health and how well the treatment is working. Doctors will also perform blood tests and scans to check for side effects and see how your body reacts to the drugs.
The study is currently active but is not looking for new participants. Locations include clinics in Los Angeles and Santa Monica, California, as well as Louisville, Kentucky.
- 1The study combines a new cancer vaccine with an existing immunotherapy treatment.
- 2Participants must have advanced lung cancer with specific protein levels (PD-L1) and a history of smoking.
- 3Researchers are carefully tracking side effects and how the immune system responds to the vaccine.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.